document.getElementById('index-articles-list').innerHTML = `

Reply to the Letter to the Editor by Perez et al. regarding "Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: a pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials"

致Perez等人的信关于“接受全盆腔脏器系膜切除术或新辅助治疗后的选择性观察等待的患者的生存情况：CAO/ARO/AIO-12和OPRA随机II期临床试验的合并分析”答复

J Garcia-Aguilar,H Williams,E Fokas et al.

Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 9:S0923-7534(25)00110-3. DOI:10.1016/j.annonc.2025.03.004

Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial

阿霉素为基础的一线化疗后用于治疗晚期非脂肪肉瘤患者的瑞戈非尼维持疗法：一项双盲随机试验

N Penel,A Italiano,J Wallet et al.

Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 8:S0923-7534(25)00136-X. DOI:10.1016/j.annonc.2025.03.024

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis

肿瘤浸润淋巴细胞和高剂量重组白介素-2疗法治疗晚期皮肤黑色素瘤安全性的系统评价和meta分析

S Martín-Lluesma,U Dafni,K Vervita et al.

Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 8:S0923-7534(25)00135-8. DOI:10.1016/j.annonc.2025.04.001

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study

PALMARES-2研究：HR+/HER2-晚期乳腺癌一线使用palbociclib、ribociclib或abemaciclib联合内分泌治疗的现实世界疗效对比研究

L Provenzano,M V Dieci,G Curigliano et al.

Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 7:S0923-7534(25)00134-6. DOI:10.1016/j.annonc.2025.03.023

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma

III期皮肤黑色素瘤辅助治疗的疗效分析

P Grover,S N Lo,I Li et al.

Annals of oncology : official journal of the European Society for Medical Oncology. 2025 Apr 7:S0923-7534(25)00132-2. DOI:10.1016/j.annonc.2025.03.021

`; document.getElementById('index-articles-more').href = `https://i.iikx.com/journal/1569-8041.html`; document.getElementById('index-articles-more').innerHTML='更多内容'; document.getElementById('index-articles-more').style="float:right;background:var(--primary-color);color:#fff;font-size:13px;border-radius:5px;padding:0px 10px;margin-right:5px;line-height:1.7"; document.getElementsByClassName('index-artcles')[0].style.display = 'block'; document.getElementById('showJournalIndexUrl').style.display = 'block'; document.querySelector('#showJournalIndexUrl a').href = `https://i.iikx.com/journal/1569-8041.html`;